Retraction. We now observe alterations in a number of the properties of arl mutants of Escherichia coli; some of these properties were originally described by us in a paper entitled "DNA from recombinogenic bacteriophages generated by arn mutants of Escherichia coli is cleaved by single-strandspecific endonuclease Si", John B. Hays and Brent E. Korba, which appeared in number 12, December 1979, of Proc. Natl. Acad. Sci. USA (76,(6066)(6067)(6068)(6069)(6070). With respect to these latter phenomena, we now find that X phages grown on arl bacteria ("Arl-phages") recombine only 1.2-1.5 rather than 3-5 times as much as "Arl+" phages in subsequent onestep-growth infections, and DNA from Arl-phages no longer appears sensitive to the single-strand-specific S1 nuclease. Some arl phenomena described elsewhere-e.g., decreased resistance to EcoRII restriction by arl phages and enhanced recombination of Arl-plasmids-remain approximately unchanged. The phage-growth properties of both wild-type and arl bacteria using our standard phage growth medium are greatly altered from those described previously, and some genetic properties of the mutants appear changed. It remains to be determined to what extent alterations in arl properties are due to changes in growth medium and/or genetic instability. Fuller accounts of the present status of arl phenomena appear elsewhere (Hays, J. B. & Korba, B. E., J. Mol. Biol. and Cell, in press).
mor weights and volume. The The development of new methods for the treatment of pancreatic cancer in man has been hampered by the lack of suitable experimental models of this disease. Recently, several animal models of transplantable pancreatic tumors with acinar and ductal phenotypic characteristics have been developed (1) (2) (3) .
Regulation of growth of the exocrine pancreas appears to be hormonal in nature. The gastrointestinal hormones cholecystokinin (CCK) and secretin are the chief endocrine stimulants of pancreatic exocrine secretions (4) . An important, recently established action of CCK, secretin, and gastrin is their ability to stimulate the growth of the exocrine pancreas (4) (5) (6) (7) . The role that these gastrointestinal hormones play in the development and growth of pancreatic cancer is not clearly understood, but it is likely that they may influence the growth of malignant cells of the pancreas (8) . Townsend et al. (8) have shown that caerulein, which is structurally related to CCK, and secretin stimulate the in vivo growth of hamster pancreatic cancer. CCK, secretin, and gastrin can also stimulate the growth of rat stomach cancer cells in tissue cultures (9) .
Somatostatin may also be important in regulating the activities of the gastrointestinal tract and the endocrine and exocrine pancreas (10) . Studies carried out in several species, including human beings, have shown that somatostatin and its analogs exert inhibitory actions on the endocrine and exocrine pancreas as well as on the stomach and gut. These actions include inhibition of the release of insulin and glucagon and suppression of the secretion or action (or both) of gastrin, secretin, and CCK (11) (12) (13) (14) . Clinical studies have demonstrated that somatostatin or its analogs inhibit insulin secretion in patients with insulinomas and glucagon release in cases of glucagonomas (11, 15, 16) . The secretions of ectopic endocrine tumors of the pancreas, including gastrin secreted from gastrinomas and vasoactive intestinal peptide (VIP) released from vipomas, are also suppressed by somatostatin or its analogs (17, 18) .
Sex steroids may also play a role in the growth of normal and cancerous pancreas (19) (20) (21) . The incidence of carcinoma of the pancreas is greater in males, indicating that this neoplasia may be androgen sensitive. The presence of specific receptors for estrogen and androgen in pancreatic cells indicates that sex hormones may influence neoplastic cell processes (19) (20) (21) . All of these findings suggest that pancreatic adenocarcinomas may be sensitive to both gastrointestinal and sex hormones.
Inhibition of the growth of endocrine-dependent mammary, prostate, and pituitary tumors by analogs of hypothalamic hormones has recently been demonstrated (22) (23) (24) In the second experiment with hamsters bearing the ductal pancreatic adenocarcinoma ( (5) (6) (7) . Although secretin is not as potent as CCK, it also increases pancreatic weight, DNA, RNA, and protein content (7) . Similarly, gastrin has a potent trophic effect on the exocrine pancreas and the mucosa of the large and small bowel. Chronic administration of pentagastrin to antrectomized rats prevents the decrease in pancreatic and colonic weight (6, 7) .
The effects of gastrointestinal hormones on the growth of pancreatic tumors have been studied by Townsend et al. (8) .
They were able to demonstrate stimulation of the growth of ductal carcinoma by administration of high doses of caerulein in hamsters, alone or in combination with secretin (8) . The mechanisms through which these hormones stimulate growth of these tumors are not fully understood. CCK is the major hormonal regulator of pancreatic acinar cell function. CCK receptors have been found in intact pancreatic acini and in particulate fractions prepared from the whole pancreas (32) . Secretin is rapidly and specifically bound to pancreatic membranes and exerts its greatest effect on the pancreatic ducts (3). Binding of 1251-labeled secretin to ductal pancreatic tumors of hamsters has also been demonstrated (3) .
Somatostatin inhibits not only the liberation of insulin and glucagon but also the release or action (or both) of secretin, gastrin, CCK, and other gastrointestinal peptides such as VIP and motilin (11) (12) (13) (14) (15) (16) (17) (18) . Somatostatin has been shown to suppress exocrine pancreatic secretion in rats, dogs and humans (11, 12, 14, 18 (34) and found that testosterone levels were significantly reduced in patients with pancreatic carcinoma when compared to controls, possibly due to the uptake and metabolism within the tumor (34, 35) . The findings that pancreatic adenocarcinomas might be sex steroid dependent are supported by evidence from xenografts of human pancreatic adenocarcinomas in nude mice (36) . Testosterone stimulated tumor growth rate, whereas cyproterone, an antiandrogen, significantly inhibited it (36) . Estrogen receptors have also been -demonstrated in 7,12-dimethylbenz[a]anthracene-induced pancreatic carcinomas in rats and in human pancreatic carcinomas (37) . The findings reported here support the view that both acinar and ductal pancreatic tumors may be sex hormone sensitive. Surgical castration of animals bearing these pancreatic tumors or medical castration by chronic administration of the agonist [D-Tip6]LH-RH resulted in an inhibition, but not a complete suppression, of tumor growth.
It is apparent from our data that dual mechanisms may be involved in the control of growth of these pancreatic tumors. One mechanism may operate through gastrointestinal hormones that exert trophic effects on pancreatic tumor growth. Administration of somatostatin analogs slows the growth of the pancreatic tumor by inhibiting the release or action (or both) of gastrointestinal hormones. The second mechanism might involve stimulation of pancreatic tumor by sex steroids. Surgical or medical castration decreases tumor growth by eliminating the stimplating effect of sex steroids.
It is possible that a more efficacious method of inhibition of pancreatic carcinoma could result from a combination of somatostatin analog with [D-Trp6]LH-RH or with'an antagonistic analog of LH-RH. In the future it should be possible to administer such combinations in the form of polymeric microcapsules for constant controlled release. In any event, the findings reported' here could be of clinical importance and might lead to the development of 4 new method for the treatment of pancreatic carcinoma based on administration of some analogs of somatostatin, [D-Trp6]LH-RH, or combinations thereof.
